Aarti Drugs Ltd

NSE
AARTIDRUGS •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Aarti Drugs Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
58.52% Gain from 52W Low
0.5
TTM PE Ratio
Below industry Median
25.4
Price to Book Ratio
Above industry Median
3.8
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is much higher than 1
2.9
RSI
RSI is mid-range
36.6
MFI
MFI is mid-range
54.5

Aarti Drugs Ltd Key Financials

*All values are in ₹ Cr.

Aarti Drugs Ltd shareholding Pattern

Promoter
57.5%
Foreign Institutions
2.1%
Mutual Funds
5.2%
Domestic Institutions
5.3%
Public
35.2%

Aarti Drugs Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
509.90
10Day EMA
518.10
12Day EMA
519.80
20Day EMA
522.40
26Day EMA
522.40
50Day EMA
518.70
100Day EMA
513.80
200Day EMA
503.20
Delivery & Volume
Resistance & Support
498.60
Pivot
Resistance
First Resistance
502.20
Second Resistance
506.80
Third Resistance
510.40
Support
First Support
494
Second support
490.40
Third Support
485.80
Relative Strength Index
36.57
Money Flow Index
54.53
MACD
-2.59
MACD Signal
2.24
Average True Range
15.84
Average Directional Index
14.67
Rate of Change (21)
-5.52
Rate of Change (125)
-14.63

Aarti Drugs Ltd Company background

Founded in: 1984
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, AntiInflammatory, Antidiabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a whollyowned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two RD divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 199495, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company.During the year 199697, the company started their production of secnidazole and dichlofenac sodium. During the year 200001, they started the commercial production of Pharmaceutical Ingredients. During the year 200203, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 200304, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 200405, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 200506, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 200607, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 200809, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg.During the year 200910, the company carried out process improvement work in bulk drugs, such as antihistaminic/antiallergic, antiinflammatory and antidiabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012.During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh. During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs. In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.
Read More

Aarti Drugs Ltd FAQs

Aarti Drugs Ltd shares are currently priced at 497.6 on NSE and 497.35 on BSE as of 2/28/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Aarti Drugs Ltd [AARTIDRUGS] share was 35.84. The Aarti Drugs Ltd [AARTIDRUGS] share hit a 1-year low of Rs. 313.9 and a 1-year high of Rs. 645.75.

The market cap of Aarti Drugs Ltd is Rs. 4607.78 Cr. as of 2/28/2024 12:00:00 AM.

The PE ratios of Aarti Drugs Ltd is 28.98 as of 2/28/2024 12:00:00 AM.

The PB ratios of Aarti Drugs Ltd is 4.12 as of 2/28/2024 12:00:00 AM

The Mutual Fund Shareholding was 5.18% at the end of 2/28/2024 12:00:00 AM.

You can easily buy Aarti Drugs Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage